The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Ignyta; Merck; MSD; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Ignyta; Merck; MSD; Novartis; Pfizer; Roche; Takeda
 
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Janssen-Cilag (Inst); MSD (Inst); Roche (Inst)
Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.
 
Martin Reck
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; Roche/Genentech
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; Roche/Genentech
 
Tudor-Eliade Ciuleanu
Consulting or Advisory Role - A&D Pharma; Amgen; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Sanofi; SERVIER
Travel, Accommodations, Expenses - A&D Pharma; Amgen; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Ipsen; Janssen; Lilly; Merck; MSD; Novartis; Pfizer; Roche/Genentech; Sanofi; Servier
 
Manuel Cobo Dols
No Relationships to Disclose
 
Michael Schenker
Research Funding - Amgen; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; MSD; Pfizer/EMD Serono; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Bogdan Zurawski
No Relationships to Disclose
 
Juliana Menezes
No Relationships to Disclose
 
Eduardo Richardet
No Relationships to Disclose
 
Jaafar Bennouna
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD Oncology; Novartis; roche; SERVIER
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis; Roche; SERVIER
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Roche
 
Enriqueta Felip
Consulting or Advisory Role - Abbvie; AstraZeneca; BerGenBio; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Guardant Health; Janssen; Lilly; Medscape; Merck KGaA; Merck Sharp & Dohme; Novartis; Pfizer; priME Oncology; Roche; Samsung; Takeda; touchIME
Speakers' Bureau - AbbVie; Abbvie; AstraZeneca; BerGenBio; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Guardant Health; Janssen; Lilly; medscape; Merck KGaA; Merck Sharp & Dohme; Novartis; Pfizer; Prime Oncology; Roche; Samsung; Takeda; touchIME
Research Funding - EMD Serono (Inst); Merck (Inst)
Other Relationship - GRÍFOLS
 
Oscar Juan-Vidal
Consulting or Advisory Role - AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Pfizer; Roche/Genentech; Takeda
Research Funding - AstraZeneca Spain (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Roche/Genentech
 
Aurella Alexandru
Consulting or Advisory Role - Boehringer Ingelheim; Roche
Speakers' Bureau - Bristol-Myers Squibb; Novartis; Sandoz
Expert Testimony - Bristol-Myers Squibb; Novartis; Sandoz
 
Hiroshi Sakai
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Merck KGaA; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical
 
Arnaud Scherpereel
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; MSD Oncology; Roche
Speakers' Bureau - AstraZeneca; Roche Pharma AG
Research Funding - Bristol-Myers Squibb (Inst); MSD Oncology (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD Oncology; Roche
 
Shun Lu
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Hutchison MediPharma; Roche; Simcere
Speakers' Bureau - AstraZeneca; Hansoh; Roche
Research Funding - AstraZeneca; Bristol-Myers Squibb; HenRui; Hutchison MediPharma; Roche
 
Thomas John
No Relationships to Disclose
 
David Paul Carbone
Employment - James Cancer Center
Honoraria - AstraZeneca; Nexus Pharmaceuticals Inc
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; Biothera; Boehringer Ingelheim; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Genentech/Roche; Helsinn Therapeutics; Incyte; Inivata; Loxo; Merck; Novartis; Peregrine Pharmaceuticals; Pfizer; Synta; Synta
Research Funding - Bristol-Myers Squibb
 
Stephanie Meadows-Shropshire
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Jinchun Yan
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Luis G. Paz-Ares
Leadership - Altum Sequencing; European Medicines Agency (I); Genomica
Honoraria - Advanced Accelerator Applications; Amgen; AstraZeneca; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Incyte; Ipsen; Lilly; Merck Serono; MSD; Novartis; Pfizer; PharmaMar; Roche/Genentech; Sanofi; Servier; Sysmex
Research Funding - AstraZeneca; Bristol-Myers Squibb
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; MSD; Pfizer; Roche; Takeda
Other Relationship - Amgen (I); Ipsen (I); Merck (I); Novartis (I); Pfizer (I); Roche; Roche (I); Sanofi (I); SERVIER (I)